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Summary
Results from recent clinical trials have shown that stroke is preventable both before and after
symptomatic cerebrovascular disease through a change in lifestyle, medical therapy and surgical procedures.
Risk factor control, antiplatelet agents, anticoagulation, and carotid endarterectomy have been proven to be
effective under appropriate clinical circumstances. In this update, we shall highlight the areas in which
scientific evidence is available. (HK Pract 1998;20:67-77)
Introduction
Stroke is a major neurological
disease and a leading cause of death
and disability in Hong Kong. Some
breakthrough has been achieved
recently in acute stroke treatment,1'2
but prevention remains the optimal
strategy for reducing the burden of
stroke in our community. Stroke is a
he te rogeneous syndrome wi th
different causes, types, and severity.
Ischaemic stroke is the most common,
intracerebral haemorrhage the second,
and subarachnoid haemorrhage the
least common among the three major
stroke types.3 Therapy should be
formulated according to the clinical
characteristics and risk factor profile
of individual patients. Primary stroke
prevention refers to prevention of
stroke in people with no history of
cerebrovascular symptoms, and
secondary prevention applies to
patients who have had a stroke or
transient ischaemic attack.
Epidemiological and cohort
s t u d i e s have i d e n t i f i e d many
modifiable risk factors for stroke.
Risk factors identification allows us
not only to recognize people at risk of
stroke but also to promote a healthy
lifestyle in the general population.
Antithrombotic therapy should be
considered in people at risk of
cerebral ischaemia, as thromboembo-
lism is a major pathogenic mechanism
for ischaemic stroke. Finally,
corrective procedures are available
for carotid artery stenosis. These
measures in general apply to both
p r i m a r y and secondary stroke
prevention (Table 1).
* Address for correspondence: Dr YL Yu, Suite 1201, Lane Crawford House, 70 Queen's Road Central, Hong Kong.
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2. Angioplasty and stenting
Modifiable Risk Factors
Hypertension
Both systolic and diastolic blood
pressures are independently associ-
ated with a 4 to 5 times increased risk
of stroke of all types.4 Hypertension
promotes atherosclerosis in large and
medium-sized arteries, arterioscle-
rosis in small penetrating arteries, and
Action
Screen for hypertension; keep systolic and
diastolic blood pressure around 140 and
85 mmHg, respectively
Check potential cardioembolic source;
screen for other causes of stroke; see
Tables 2 and 3
Check ECG and echocardiography; see
Tables 3 and 4
Screen for undiagnosed diabetes mellitus;
aim at strict glycaemic control
Screen and control dyslipoproteinaemia
Advise to quit smoking; consider nicotine
gum or pad
Advise to reduce drinking
Reduce weight
Practise regular exercise
Start oral aspirin for secondary prevention
of stroke and other vascular events;




cardiac diseases of ischaemic and
hypertensive types. These patho-
logical processes may, in turn, cause
stroke through thrombosis, embolism,
occlusion of small vessels, or arterial
rupture. One meta-analysis revealed
a 42% reduction in the incidence of
stroke and a 45% reduction in the
incidence of fatal stroke with only 5
to 6mm Hg decrease in the mean
diastolic pressure following treat-
ment.5 The Systolic Hypertension in
the Elderly Program (SHEP) reported
a 36% decline in stroke risk with
11 mm Hg reduct ion in the mean
systolic pressure.6 In a local study,
74% of pa t i en t s presented wi th
cerebral haemorrhage were hyperten-
sive.7 Thus, early detection and good
control of hypertension is one of the
most important factors in the primary
prevention of stroke. The same
applies to secondary prevention. The
systolic and diastolic blood pressures
should be kept around 140 mmHg and
85 mmHg, respectively, to minimise
the risk of stroke and other complica-
tions.8, 9
Cardiac diseases
About one in f ive i schaemic
strokes are caused by cardioembo-
l i sm. 1 0 Table 2 summarises the
clinical, topographical, and neuro-
radiological features of cardioembolic
stroke. Nevertheless, the presence of
a potential cardioembolic source in a
patient with cerebral ischaemia may
be co-incidental . Other possible
causes of stroke, such as carotid
artery stenosis and prothrombotic
states, should also be considered.
Different cardiac conditions have
varying risks of causing strokes
(Table 3), and the chance of detecting
s u c h c o n d i t i o n s d e p e n d s o n
thoroughness of the evaluat ion.
Long-term antithrombotic therapy is
available to reduce the risk of embolic
stroke at the expense of an increased
r i sk of sys temic and cerebral
haemorrhages.
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Table 2: Features of cardioembolic stroke
or ideomotor apraxia
Table 3: Causes and management of cardioembolic stroke*
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Atrial fibrillation (AF) affects
1% of the general population, 6% of
people aged above 65 years, and 10%
of those over 75 years of age.11 AF
increases the risk of ischaemic stroke
through systemic embolization of
stasis-induced left atrial thrombi. The
continued decline in the frequency of
rheumatic heart disease will make
non-va lvu l a r a t r ia l f i b r i l l a t i o n
(NVAF) the commonest cause of this
arrhythmia. Silent cerebral infarcts
on computed tomography of the brain
are present in about 25% of patients
with NVAF, and are often multiple or
b i l a t e r a l . 1 2 N e v e r t h e l e s s , t h e
associated cardiac abnormalities,
coexistent cardiovascular diseases
and intrinsic cerebrovascular diseases
may account for 25 to 33% of all
strokes associated with AF.13 Recent
randomised trials have revealed an
increased risk of stroke (about 5% per
year or 5 to 7 times as controls) in
patients with NVAF and have proved
the safety and benefit of long-term
ant i coagu la t ion with warfar in . 4
Nevertheless, the actual risk of stroke
is affected by a number of clinical and
echocardiographic factors (Table 4).
Using meta-analysis , the overall
relative r isk reduction in stroke
among patients treated with warfarin
as compared with placebo is 64%, and
the corresponding benefit of aspirin is
22%.14 For patients with AF due to
rheumatic heart disease, the benefit of
long-term anticoagulation is proven.14
Long-term anticoagulation (with
warfarin) is therefore an established
prac t i ce for secondary s t roke
prevention in patients with AF due to
valvular heart disease or non-valvular
causes (Table 3), and is increasingly
employed in primary prevention.
However, it must be emphasised that
careful consideration of compliance
and other factors must be given
before starting treatment and that
adequate instructions be communi-
cated to patients and their relatives
in order to reduce the r i s k of
haemorrhagic complications. Low-
intens i ty an t icoagula t ion (with
in terna t ional normal ized rat ios
between 2 to 3) carries an extra 1 to
2% risk of severe bleeding, including
an 0.3% a n n u a l i n c i d e n c e of
intracerebral haemorrhage.15 Older
patients (more than 75 years) have a
higher risk of stroke but manifest
Table 4: Risk factors for stroke in non-valvular atrial fibrillation




Previous history of stroke
.- .Transient ischaemic attack
- dysfunction .
greater toxicity to warfarin. Patients
at lower risks for cardioembolism and
those with contraindications for
warfarin should be given low-dose
aspirin at 325 mg per day to achieve
stroke prevention.4,14'15 Other medical
and surgical therapies are also useful
in individual cardiac diseases.
Glucose tolerance
Diabetes mellitus is associated
wi th c e r e b r o v a s c u l a r d i s ea se
(including atherosclerosis and/or
small vessel disease) directly and
indirectly via coronary artery disease,
hypertension, abnormal lipids, and
obesity.16 The re la t ive r i sks of
ischaemic stroke and stroke of all
types are elevated by two-folds in
both diabetic men and women.4 In a
local study of 176 Chinese patients
wi th acute s troke, the overa l l
prevalence of diabetes mellitus and
impaired glucose tolerance was
33.5% and 21.0% respectively, with a
higher prevalence being found in
patients with cerebral infarction.1 7
Forty percent of those with diabetes
m e l l i t u s w e r e p r e v i o u s l y
undiagnosed.
Since undiagnosed diabetes
mellitus is a distinct health problem
in our elderly population, it may be
important to screen for diabetes
mellitus as part of primary health care
of the elderly particularly those who
are at a higher risk. Treatment should
aim at both strict glycaemic control as
well as control of all risk factors for
cardio- and cerebrovascular diseases,
although the influence of the former
on the risk of stroke remains
unknown.
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Cigarette smoking
Cigarette smoking increases the
risk of ischaemic stroke by 2 to 3
times t h rough the induc t ion of
atherosclerosis and ischaemic heart
disease.4 In addition, cigarette
smoking increases blood levels of
fibrinogen and other clotting factors,
promotes platelet aggrega t ion ,
elevates the haematocrit, reduces the
level of high-density l ipoprotein
cholesterol, produces acute rise in
arterial blood pressure, and enhances
the breakdown of elastic tissue within
arteries.16 The latter two effects may
lead to arterial rupture and intracere-
bral or subarachnoid haemorrhage.18
The risk of stroke for smokers is
higher in women than men, becomes
less with increasing age, and is
proport ional to the number of
cigarettes smoked per day.19 The risk
of stroke of all types decreases
promptly towards the level of non-
smokers within five years of quitting
in both men and women."
Alcohol abuse
Recent studies have clarified the
role of alcohol consumption in stroke.
Low levels of alcohol intake (one to
two drinks per day) appears to reduce
the risk for ischaemic stroke via
reducing the risk of ischaemic heart
disease, improving the lipid pattern,
increasing the level of prostacyclin,
and a c t i v a t i n g the f i b r i n o l y t i c
system.16 Higher levels of drinking,
especially following acute intoxica-
tion, increases the risk for ischaemic
and haemorrhagic strokes by 3 to 4
times via haemoconcentration (pro-
ducing hyperviscosity), hypertension
(increasing the risk for intracerebral
bleeding), rebound thrombocytosis
(causing a prothrombotic state),
cardiac arrhythmias (generat ing
thromboemboli or hypoperfusion),
and interactions with smoking (as
smoking is more frequent among
heavy drinkers).16
Blood lipids
High level of total and low-
densi ty l ipoprotein cholesterols,
reduced l eve l o f h i g h - d e n s i t y
lipoprotein cholesterol, and increased
rat io of low- to h i g h - d e n s i t y
lipoprotein cholesterols constitute
d y s l i p o p r o t e i n a e m i a , w h i c h is
associated with premature atheroscle-
rosis and ischaemic heart disease.20
The association between dyslipopro-
te inaemia and stroke has been
established recently. Lipid lowering
agents have been found to reduce the
risk of fatal and non-fatal strokes as
well as retard the progression of
carotid atherosclerosis.4
Obesity
Obesity is p robab ly not an
independent factor but related to
dyslipoproteinemia, hypertension,
hyperinsulinaemia, glucose intoler-
ance, and lack of exercise.16 In
experimental animal studies, caloric
restriction prolongs survival.21
Lack of exercise
Exercise reduces blood pressure,
body weight, and platelet aggregation
but improves lipid pattern and
sensitivity to insulin.16 These effects
may explain the association between
sedentary lifestyle and strokes of all
types in both men and women.
Others
Higher-dose oral contraceptives
have been found to increase the risk
of stroke in women over 35 years of
age, smokers, hypertensives, and
migraineurs.1 6 Although low-dose
oral contraceptives do not increase
the risk of stroke,22 oral contracep-
tives should be avoided in women at
high risk for stroke. Post-menopausal
oestrogen replacement may reduce
cardio- and cerebrovascular events
and prevent osteoporosis, but there is
an increased risk of endometrial and
b r e a s t cance r . 2 2 P r o s p e c t i v e
randomised tr ials are awaited to
clar i fy the benefits of oestrogen
replacement, antioxidant vitamins,
dietary potassium, or polyunsaturated




pa t i en t s wi th a high risk of
cardioembolism has been discussed
(see Table 3).
Antiplatelet agents
Use of aspirin in the primary
p reven t ion of stroke r e m a i n s
controversial among healthy subjects.
Studies of healthy subjects taking
aspirin of various doses have reported
(Continued on page 74)
72
Primary and Secondary Prevention of Stroke
UPDATE ARTICLE
no benefit in the risk of ischaemic
stroke, strokes of all types, fatal
stroke, or fatal vascular events.4 '14
While low-dose aspirin protects
against first myocardial infarctions,
there may be a small increase in the
risk of intracerebral haemorrhage.
Meta-analysis of data from large
clinical trials on antiplatelet agents
shows that aspirin reduces vascular
mortali ty by 15% and non-fatal
v a s c u l a r e v e n t s ( s t r o k e a n d
myocardial infarction) by 30%.23'24
The dosage is less important; 300 mg
daily is as effective as 1.3 gm daily,
but produces less gastrointestinal
upset.25
Two major multicentre trials26'27
have shown that ticlopidine 250 mg
twice daily is as effective as aspirin
in secondary stroke prophylaxis. It is
not ulcerogenic but may cause skin
rash, leucopenia, aplastic anaemia and
b l e e d i n g t endency , and rarely
cho les ta t i c j a u n d i c e or raised
transaminases. In general, it is given
to pa t ien ts who cannot tolerate
aspirin.
Carotid artery stenosis
Ext rac ran ia l ca ro t id ar tery
stenosis is an established risk factor
for symptomatic and silent stroke.
T h e i m m e d i a t e p a t h o g e n i c
mechanisms for cerebrovascular
ischaemic symptoms and/or signs in
carotid artery stenosis are two:
thromboembolic (especially with an
ulcerated plaque) and haemodynamic
(when there is near or total occlusion,
especially with poor collaterals and/
or systemic hypotension). The risk
for stroke is non-uniform but affected
by factors such as occurrence of
symptoms , degree of s t enos i s ,
presence of ulceration, contralateral
occlusion, presence of collaterals,
number of other risk factors and
cerebral infarction on computed
tomography of the brain.28 Standard
contrast angiography remains the gold
standard for p rov id ing accurate
images of the carotid arteries, the
proximal vessels and the intracranial
vascula ture . Diameter stenosis
(comparing the diameter of the
internal carotid artery above the
stenosis as the denominator with the
diameter of the narrowest part as the
numerator) should be used.29 This is
the method used in the Nor th
American Symptomatic Carotid
Endarterectomy Trial. Contemporary
data on the prevalence of carotid
artery stenosis is not available in
Hong Kong Chinese. In addition, the
risk of first and recurrent strokes is
u n k n o w n in local pa t ien ts wi th
moderate or severe carotid artery
stenosis.
Carotid artery stenosis can be
corrected by carotid endarterectomy
or p e r c u t a n e o u s t r a n s l u m i n a l
angioplasty with or without stenting.
Carotid endarterectomy carries a
s igni f icant perioperative risk of
morbidity and mortality of 5 to 7% or
more.29 The preoperative carotid
arteriography also contributes an
additional risk to the procedure.
Patients with severe asymptom-
atic carotid artery stenosis have a 1.5
to 2% annual stroke rate.4 Results of
four randomised clinical trials of
carotid endarterectomy in patients
with severe asymptomatic carotid
disease were published.14'30 Only the
Asymptomatic Carotid Atherosclero-
sis Study found a marginal benefit
f rom surgery in a symptomat ic
stenosis of 60% or more by diameter:
1% per year absolute reduction in
stroke risk over a five-year projected
period despite a remarkably low
perioperative risk of 2.3%.30 Never-
theless, there was no reduction in the
major strokes or deaths. There was
no benefit in females, and there was
no relation between the benefit and
the degree of stenosis. At present,
scientific data do not unequivocally
support carotid endarterectomy as an
effective way of pr imary stroke
prevention in patients with asymp-
tomatic carotid artery stenosis of any
severity so the prophylactic measures
are antithrombotic therapy with low-
dose aspirin and modification of risk
factors.29
In gene ra l , p a t i e n t s w i th
transient ischaemic attacks related to
severe (70 to 99% by diameter)
carotid artery stenosis have a 12 to
13% rate of stroke in the first year
and a cumulative rate of 30 to 35% in
five years, whereas those presenting
with strokes have a 5 to 9% annual
rate of recurrence and a five-year rate
of 25 to 45%.29 After successful
carotid endarterectomy, patients who
presented with transient ischaemic
attacks continue to have a 1 to 2%
annual risk of recurrent stroke, while
a presenting history of stroke carries
a 2 to 3% per year rate of subsequent
stroke. Surgery has been proven to be
inferior to the best medical manage-
ment if the symptomatic stenosis is
less than 30%.29 Contemporary
guidelines of carotid endarterectomy
are summarised in Table 5.
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Indicated in patients with 70 to 99% stenosis if
peri-operative morbidity and mortality rate <6%
Not indicated in patients with < 70% stenosis
even if surgical risk <6%
Not indicated when surgical risk approaches
10% irrespective of degree of stenosis
Considered acceptable in patients with < 70%
stenosis in an ongoing prospective contemporary
randomized trial plus <6% surgical risk
Asymptomatic 1. Not definitely indicated in any patients
2. Considered acceptable in patients with > 75%
stenosis plus < 3% surgical risk
3. Not indicated when surgical risk is >3%
: : :; irrespective of degree of stenosis
* degree of stenosis as defined by the North American Symptomatic Carotid
Endarterectomy Trial
The o p t i m a l s t r a t e g y fo r
managing patients with combined
coronary artery and carotid disease
remains unresolved. Meta-analysis of
the available reports indicates that
combined carot id and coronary
surgery carr ies the same peri-
operative stroke rate (6.2%) as when
carotid endarterectomy precedes
coronary artery bypass g ra f t ing
(stroke rate = 5.3%) and that the
stroke rate is h ighes t (10.0%) if
carotid surgery follows coronary
s u r g e r y . 2 9 N e v e r t h e l e s s , t h e
probability of myocardial infarction
(11.5%) and death (9.4%) is greater
when carotid surgery precedes
coronary artery bypass grafting than
when the order is reversed (myocar-
dial infarction rate = 2.7% and death
rate - 3.6%). Simultaneous surgery
has a 4.7% probability of myocardial
infarction and a 5.6% probability of
death. Thus, a prospective ran-
domised trial is needed to resolve the
controversy. Meanwhile, combined
carotid and coronary surgery appears
to be acceptable for patients in whom
both procedures are of proven benefit.
P e r c u t a n e o u s t r a n s l u m i n a l
angioplasty with or without stenting
in cerebral artery stenosis is at the
experimental stage.14 This procedure
carries the risk of cerebral or retinal
embolization. While prospective data
are being collected to build up our
e x p e r i e n c e on the p rocedure ,
randomised control trials are awaited
to confirm its usefulness.
Conclusion
Recent clinical studies have
provided important data to guide
primary and secondary prevention of
stroke. Family physic ians can
therefore play an important role in
stroke prevention. They are in a
better position than specialists in
screening and identifying risk factors
of stroke, promoting a healthy life-
style and providing routine manage-
ment of modifiable risk factors. In
most patients with ischaemic stroke,
the pathogenic mechanism is athero-
thrombosis, and antiplatelet therapy is
useful in secondary prevent ion .
Family physicians should be able to
monitor the long-term antiplatelet
therapy, whereas complicated or
unusual cases should be referred to
neurologists. Anticoagulation is
indicated for prevention of cardi-
oembolic stroke provided contraindi-
cations are absent. Since long-term
anticoagulation is a complex issue, it
w o u l d be b e t t e r h a n d l e d by
specialists. If the perioperative risk
is acceptable, carotid endarterectomy
for severe stenosis is beneficial for
symptomatic patients but is contro-
versial in asymptomatic patients.
Patients with symptomatic carotid
artery stenosis should be referred to
specialists for assessment as carotid
endarterectomy or angioplasty may
have to be considered. Finally,
ongoing clinical trials will help
clarify the uncertain areas in stroke
prevention. •
(Continued on page 77)
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1. Stroke is a major neurological disease and a leading cause of death and disability. Family physicians play an important
role in stroke prevention.
2. Stroke is a heterogeneous syndrome, and specific therapy varies according to the clinical setting and risk factor profile
of individuals.
3. Epidemiological and cohort studies have identified hypertension, atrial fibrillation and other types of cardiac diseases,
diabetes mellitus, dyslipoproteinaemia, smoking and alcohol abuse, obesity and lack of exercise as the modifiable
risk factors for stroke.
4. Antithrombotic therapy should be considered in people at risk of cerebral ischaemia. Antiplatelet therapy is effective
in secondary prevention of atherothrombotic stroke. Anticoagulation prevents cardioembolic stroke, but
contraindications should be noted.
5. Corrective procedures are available for carotid artery stenosis. If the perioperative risk is acceptable, carotid
endarterectomy for severe stenosis is beneficial for symptomatic patients but is controversial in asymptomatic patients.
6. Complicated or unusual cases should be referred to neurologists.
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